ArticleFrontiers in pharmacology2023

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).

Fatema Alrashed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.